Tag: drug patent

Novartis loses over $2.7 billion in patent appeal of multiple sclerosis drug

A U.S. appeals court on Tuesday ruled that a patent related to Swiss drugmaker Novartis AG's blockbuster multiple sclerosis...

The new direct acting anticoagulant in the anticovid portfolio of Promomed Group

Promomed Group received marketing authorization certificate for a medicinal product with nadroparin calcium as active ingredient. Nadroparin is a...

Top biopharma companies could be affected by Brazilian drug patent suspension

GlaxoSmithKline will be the most affected, as it represents 26% of the potentially impacted drugs. This is followed by Novartis at 14%, Sanofi at 11%, and both Pfizer and Bayer with 8%.